Global RNAi for Therapeutic Market by Manufacturers, Regions, Type and Application, Forecast to 2021

Consumer goods and Retailing

The New Report on RNAi for Therapeutic Market Research Report is a deep market research report in this market. This report focused on global and regional market, major manufacturers, as well as the segment market details on different classifications and applications.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Scope of the Report:
This report focuses on the RNAi for Therapeutic in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed

Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa

Market Segment by Type, covers
siRNA
miRNA
shRNA

Market Segment by Applications, can be divided into
Cancer
Cardiovascular
HBV
Other

There are 13 Chapters to deeply display the global RNAi for Therapeutic market.

Chapter 1, to describe RNAi for Therapeutic Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of RNAi for Therapeutic, with sales, revenue, and price of RNAi for Therapeutic, in 2015 and 2016;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;

Chapter 4, to show the global market by regions, with sales, revenue and market share of RNAi for Therapeutic, for each region, from 2011 to 2016;

Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;

Chapter 11, RNAi for Therapeutic market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;

Chapter 12 and 13, to describe RNAi for Therapeutic sales channel, distributors, traders, dealers, appendix and data source.

Table of Contents

Global RNAi for Therapeutic Market by Manufacturers, Regions, Type and Application, Forecast to 2021
1 Market Overview
1.1 RNAi for Therapeutic Introduction
1.2 Market Analysis by Type
1.2.1 siRNA
1.2.2 miRNA
1.2.3 shRNA
1.3 Market Analysis by Applications
1.3.1 Cancer
1.3.2 Cardiovascular
1.3.3 HBV
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA
1.4.1.2 Canada
1.4.1.3 Mexico
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany
1.4.2.2 France
1.4.2.3 UK
1.4.2.4 Russia
1.4.2.5 Italy
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China
1.4.3.2 Japan
1.4.3.3 Korea
1.4.3.4 India
1.4.3.5 Southeast Asia
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil
1.4.4.2 Egypt
1.4.4.3 Saudi Arabia
1.4.4.4 South Africa
1.4.4.5 Nigeria
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Alnylam Pharmaceuticals
2.1.1 Business Overview
2.1.2 RNAi for Therapeutic Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.2 Arbutus Biopharma (Tekmira)
2.2.1 Business Overview
2.2.2 RNAi for Therapeutic Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.3 Arrowhead
2.3.1 Business Overview
2.3.2 RNAi for Therapeutic Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Arrowhead RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.4 Dicerna Pharmaceuticals
2.4.1 Business Overview
2.4.2 RNAi for Therapeutic Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.5 Mirna Therapeutics
2.5.1 Business Overview
2.5.2 RNAi for Therapeutic Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Mirna Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.6 Quark Pharmaceuticals
2.6.1 Business Overview
2.6.2 RNAi for Therapeutic Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.7 RXi Pharmaceuticals
2.7.1 Business Overview
2.7.2 RNAi for Therapeutic Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.8 Silence Therapeutics
2.8.1 Business Overview
2.8.2 RNAi for Therapeutic Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Silence Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.9 Benitec Biopharma
2.9.1 Business Overview
2.9.2 RNAi for Therapeutic Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Benitec Biopharma RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.10 miRagen Therapeutics
2.10.1 Business Overview
2.10.2 RNAi for Therapeutic Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 miRagen Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.11 Sylentis
2.11.1 Business Overview
2.11.2 RNAi for Therapeutic Type and Applications
2.11.2.1 Type 1
2.11.2.2 Type 2
2.11.3 Sylentis RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.12 Gradalis
2.12.1 Business Overview
2.12.2 RNAi for Therapeutic Type and Applications
2.12.2.1 Type 1
2.12.2.2 Type 2
2.12.3 Gradalis RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.13 Sirnaomics
2.13.1 Business Overview
2.13.2 RNAi for Therapeutic Type and Applications
2.13.2.1 Type 1
2.13.2.2 Type 2
2.13.3 Sirnaomics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
2.14 Silenseed
2.14.1 Business Overview
2.14.2 RNAi for Therapeutic Type and Applications
2.14.2.1 Type 1
2.14.2.2 Type 2
2.14.3 Silenseed RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share
3 Global RNAi for Therapeutic Market Competition, by Manufacturer
3.1 Global RNAi for Therapeutic Sales and Market Share by Manufacturer
3.2 Global RNAi for Therapeutic Revenue and Market Share by Manufacturer
3.3 Market Concentration Rate
3.3.1 Top 3 RNAi for Therapeutic Manufacturer Market Share
3.3.2 Top 6 RNAi for Therapeutic Manufacturer Market Share
3.4 Market Competition Trend
4 Global RNAi for Therapeutic Market Analysis by Regions
4.1 Global RNAi for Therapeutic Sales, Revenue and Market Share by Regions
4.1.1 Global RNAi for Therapeutic Sales by Regions (2011-2016)
4.1.2 Global RNAi for Therapeutic Revenue by Regions (2011-2016)
4.2 North America RNAi for Therapeutic Sales and Growth (2011-2016)
4.3 Europe RNAi for Therapeutic Sales and Growth (2011-2016)
4.4 Asia-Pacific RNAi for Therapeutic Sales and Growth (2011-2016)
4.5 South America RNAi for Therapeutic Sales and Growth (2011-2016)
4.6 Middle East and Africa RNAi for Therapeutic Sales and Growth (2011-2016)
5 North America RNAi for Therapeutic by Countries
5.1 North America RNAi for Therapeutic Sales, Revenue and Market Share by Countries
5.1.1 North America RNAi for Therapeutic Sales by Countries (2011-2016)
5.1.2 North America RNAi for Therapeutic Revenue by Countries (2011-2016)
5.2 USA RNAi for Therapeutic Sales and Growth (2011-2016)
5.3 Canada RNAi for Therapeutic Sales and Growth (2011-2016)
5.4 Mexico RNAi for Therapeutic Sales and Growth (2011-2016)
6 Europe RNAi for Therapeutic by Countries
6.1 Europe RNAi for Therapeutic Sales, Revenue and Market Share by Countries
6.1.1 Europe RNAi for Therapeutic Sales by Countries (2011-2016)
6.1.2 Europe RNAi for Therapeutic Revenue by Countries (2011-2016)
6.2 Germany RNAi for Therapeutic Sales and Growth (2011-2016)
6.3 UK RNAi for Therapeutic Sales and Growth (2011-2016)
6.4 France RNAi for Therapeutic Sales and Growth (2011-2016)
6.5 Russia RNAi for Therapeutic Sales and Growth (2011-2016)
6.6 Italy RNAi for Therapeutic Sales and Growth (2011-2016)
7 Asia-Pacific RNAi for Therapeutic by Countries
7.1 Asia-Pacific RNAi for Therapeutic Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific RNAi for Therapeutic Sales by Countries (2011-2016)
7.1.2 Asia-Pacific RNAi for Therapeutic Revenue by Countries (2011-2016)
7.2 China RNAi for Therapeutic Sales and Growth (2011-2016)
7.3 Japan RNAi for Therapeutic Sales and Growth (2011-2016)
7.4 Korea RNAi for Therapeutic Sales and Growth (2011-2016)
7.5 India RNAi for Therapeutic Sales and Growth (2011-2016)
7.6 Southeast Asia RNAi for Therapeutic Sales and Growth (2011-2016)
8 South America, Middle East and Africa RNAi for Therapeutic by Countries
8.1 South America, Middle East and Africa RNAi for Therapeutic Sales, Revenue and Market Share by Countries
8.1.1 South America, Middle East and Africa RNAi for Therapeutic Sales by Countries (2011-2016)
8.1.2 South America, Middle East and Africa RNAi for Therapeutic Revenue by Countries (2011-2016)
8.2 Brazil RNAi for Therapeutic Sales and Growth (2011-2016)
8.3 Saudi Arabia RNAi for Therapeutic Sales and Growth (2011-2016)
8.4 Egypt RNAi for Therapeutic Sales and Growth (2011-2016)
8.5 Nigeria RNAi for Therapeutic Sales and Growth (2011-2016)
8.6 South Africa RNAi for Therapeutic Sales and Growth (2011-2016)
9 RNAi for Therapeutic Market Segment by Type
9.1 Global RNAi for Therapeutic Sales, Revenue and Market Share by Type (2011-2016)
9.1.1 Global RNAi for Therapeutic Sales and Market Share by Type (2011-2016)
9.1.2 Global RNAi for Therapeutic Revenue and Market Share by Type (2011-2016)
9.2 siRNA Sales Growth and Price
9.2.1 Global siRNA Sales Growth (2011-2016)
9.2.2 Global siRNA Price (2011-2016)
9.3 miRNA Sales Growth and Price
9.3.1 Global miRNA Sales Growth (2011-2016)
9.3.2 Global miRNA Price (2011-2016)
9.4 shRNA Sales Growth and Price
9.4.1 Global shRNA Sales Growth (2011-2016)
9.4.2 Global shRNA Price (2011-2016)
10 RNAi for Therapeutic Market Segment by Application
10.1 Global RNAi for Therapeutic Sales Market Share by Application (2011-2016)
10.2 Cancer Sales Growth (2011-2016)
10.3 Cardiovascular Sales Growth (2011-2016)
10.4 HBV Sales Growth (2011-2016)
10.5 Other Sales Growth (2011-2016)
11 RNAi for Therapeutic Market Forecast (2016-2021)
11.1 Global RNAi for Therapeutic Sales, Revenue and Growth Rate (2016-2021)
11.2 RNAi for Therapeutic Market Forecast by Regions (2016-2021)
11.3 RNAi for Therapeutic Market Forecast by Type (2016-2021)
11.4 RNAi for Therapeutic Market Forecast by Application (2016-2021)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.1.3 Marketing Channel Future Trend
12.2 Distributors, Traders and Dealers
13 Appendix
13.1 Methodology
13.2 Analyst Introduction
13.3 Data Source List of Tables and Figures


Inquiry Before Buying



Request For Sample